USA: ACEi, ARB Use Linked to Lower Risk for Kidney Failure With Replacement Therapy

For individuals with advanced chronic kidney disease (CKD), angiotensin-converting enzyme inhibitor (ACEi) or angiotensin-receptor blocker (ARB) treatment is associated with a reduced risk for kidney failure with replacement therapy (KFRT) but not death, according to a study published online July 2 in the Annals of Internal Medicine.

Elaine Ku, M.D., from the University of California in San Francisco, and colleagues examined the association of ACEi or ARB treatment initiation with rates of KFRT and death using data from completed randomized controlled trials from 1946 through Dec. 31, 2023.

Source: Advances and More licensed by HealthDay